Save the date:
ECVPT Cardiorenal Therapeutics Symposium for practitioners
2nd July 2023, Bruges Meeting and Convention
Centre (BMCC), Bruges, Belgium

Decision making in the pharmacological management of cardiac and renal diseases in dogs and cats requires multiple factors to be taken into account to achieve the desired therapeutic outcome. Eight international experts will present the most recent evidence on which these decisions can be made and is tailored to general practitioners with a keen interest in cardiovascular and renal therapeutics.

Evidence-based and practically orientated reviews will provide practitioners with the most up-to-date evidence on which therapeutic decision making can be based, and will be supported by a series of interactive case presentations to illustrate the decision-making process that can directly be implemented in clinical practice.

In addition, the symposium is forward-looking predicting the use of two new groups of therapeutic agents (SGLT2-inhibitors and HIF prolyl hydroxylase inhibitors) in veterinary medicine. The SGLT2 inhibitors appear to have beneficial effects in both cardiac and renal patients and the HIF prolyl hydroxylase inhibitors are a novel approach to the management of anaemia
associated with chronic kidney disease.

This symposium is a must for general and specialist practitioners wanting to keep up-to-date with cardiovascular and renal therapeutics enabling them to make evidence-based therapeutic decisions to enhance the management of their cardiac and renal patients. It will also be of interest to those in academia teaching students cardiorenal therapeutics.

Pre-congress practitioners’ day organised in collaboration with EAVPT2023

The symposium is accredited as approved continuing education for veterinarians in Belgium and Germany. It has been approved in Belgium by the “Nederlandstalige Gewestelijke raad der Orde der Dierenartsen” (NGROD) and in Germany by the “Akademie für tierärztliche Fortbildung” (Academy for Veterinary Continuing Education) (ATF) of the “Bundestierärztekammer” (Federal Chamber of Veterinary Surgeons).

Meet the speakers:
Dr. Jenny Wilshaw
Dr Jenny Wilshaw is a data scientist at the Royal Veterinary
College (RVC). For her PhD she developed a clinical predictive
model to help primary care vets identify which dogs with
preclinical myxomatous mitral valve disease (MMVD) would
benefit from treatment (The HAMLET Study). She now mainly
works with data from the RVC’s hospitals and the large
VetCompass resource of electronic healthcare records with a
focus on applied solutions. Jenny will discuss the results of her
studies which have been published recently in the Journal of Veterinary Internal
Medicine and determine how to identify dogs in stage B2 MMVD that will benefit
from treatment.
Professor Adrian Boswood
Professor Adrian Boswood graduated from Cambridge
University Veterinary School in 1989. After graduation he spent
a year in mixed practice. In 1990 he joined the Royal Veterinary
College, University of London as an intern and he has worked
there ever since. He is currently Professor of Veterinary
Cardiology and holds the position of Vice Principal for Learning,
Teaching and Assessment. He obtained the RCVS Diploma in
Veterinary Cardiology in 1996 and the ECVIM Cardiology Diploma in 2001. He is
past President of the European College of Veterinary Internal Medicine. His main
research interests lie in the diagnosis, progression and treatment of acquired
canine cardiovascular diseases. He has a particular interest in myxomatous mitral
valve disease and has been involved in a number of influential clinical trials.
Adrian was the lead author of the EPIC study which demonstrated the
remarkable beneficial effects of pimobendan in stage B2 MMVD. In his talk he will
discuss the possible ways in which pimodendan benefits canine patients in this
stage of this common cardiac disease.
Professor Pascale Smets
Professor Pascale Smets received her master’s degree in
Veterinary Medicine in 2006 at the University of Ghent. After
successfully obtaining her PhD degree in internal medicine in
2011, she started an alternative residency program at the
European College of Veterinary Internal Medicine (ECVIM-ca),
subspecialty cardiology. In 2015 she became an ECVIM-ca
diplomate in cardiology and returned to Ghent University. In
2017 she was appointed a tenure track professorship with main
focus on research, teaching and clinical work in the Small Animal Department.
Pascale will discuss the knotty problem of how to treat congestive heart failure in
the patient with concomitant kidney disease, an issue that is frequently faced by
general practitioners.
Professor Harriet Syme
Professor Harriet Syme graduated from and now works at
the Royal Veterinary College, London having done an
internship and residency in small animal internal medicine
at Purdue University in the USA. Her clinical and research
interests are in nephrology/urology, hypertension and
endocrinology. She is also involved in providing pastoral
support for students and in training residents. She is a
current member of the International Renal Interest Society
chairing their awards committee. Hattie will discuss the new class of drugs, SGLT2
inhibitors which have shown great promise in human medicine in both diabetic
and heart failure patients. Hattie will discuss their potential applications to
veterinary patients.
Dr. Astrid van Dongen
Dr Astrid von Dongen graduated as a veterinarian from Utrecht
University, worked in several first opinion clinics for a number
years and then returned to university to complete an internship
and residency internal medicine of companion animals. She has
since focused most of her working life on renal disease in dogs
and cats by way of patient care, international collaboration and
education. Until last year she was an active member of the
International Renal Interest and is a previous President of IRIS. Astrid will discuss
the way in which the most appropriate treatments should be selected for dogs
with different type of glomerular disease.
Professor Dominique Paepe
Professor Dominique Paepe graduated as veterinarian at Ghent
University in 2003, became Diplomate ECVIM-CA internal
medicine in 2009 and obtained a PhD degree in Veterinary
Sciences in 2014. She is full-time appointed as Professor in internal
medicine at Ghent University, combining teaching activities,
research and clinical work. Her main research focus can be found
within the field of small animal nephrology for which was rewarded
with the “IRIS Award” in 2016. Dominique will discuss the
management of hypertension in cats where both the renal and cardiovascular
consequences of this condition need to be considered.
Dr. Sarah Spencer
Dr Sarah Spencer graduated from the University of Bristol in
2012. She returned there to complete an internal medicine
residency and became a Diplomate of the European College of
Veterinary Internal Medicine in 2018. Sarah is currently studying
for a PhD at the Royal Veterinary College, investigating the role
of the mineralocorticoid receptor in feline chronic kidney
disease and hypertension. Sarah will discuss the case for using
mineralocorticoid receptor antagonists in the management of feline hypertension.
Professor Jonathan Elliott
Professor Jonathan Elliott is currently Professor in Veterinary
Clinical Pharmacology at the Royal Veterinary College. A
Cambridge Veterinary Graduate, his PhD was in vascular
biology at the Department of Pharmacology in Cambridge
and post-graduate clinical training was undertaken at the
University of Pennsylvania. He joined the RVC in 1990 as a
lecturer in Veterinary Pharmacology and developed research interests in feline
kidney disease and hypertension and equine laminitis. He is currently an IRIS
Board member having served as President of IRIS. Jonathan will discuss a new
group of drugs, the HIF prolyl hydroxylase inhibitors and their use to manage
anaemia associated with chronic kidney disease in veterinary species.

Registration details

Because of the generous sponsorship of Ceva, IDEXX Laboratories and Elanco Animal Health, the registration fee is € 120,00 for practitioners and € 60,00 for
those currently undertaking post-graduate training (internship, residency or PhD training).